16-Dec-2025
Download PDF
Glenmark Pharmaceuticals
Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib an MHRA and NMPA approved Third - Generation EGFR-TKI from Hansoh Pharma
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
Widely read:
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
